Compare GSK plc (GSK) vs HCA Health Inc (HCA) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

HCA Healthcare (HCA) trades at $389.90, up 7.23% over the past 24 hours, with strong recent earnings beats but a bearish technical signal. The stock shows solid fundamentals with 2025 revenue of $75.60B and net income of $6.78B, supported by a P/E of 13.05 and net margin of 8.89%. However, recent news highlights guidance cuts due to payer mix shifts and rising uninsured patients, creating near-term headwinds.

The outlook is mixed: analyst consensus remains bullish with a $469.40 price target, but technical indicators and recent guidance reductions suggest caution. Key risks include margin compression and debt levels, while long-term growth drivers like capacity expansion and gene therapy research offer potential upside. Investors should weigh strong valuation metrics against operational challenges.